In this third interview of a series focused on dengue, Dr Ravindran Thayan, Head of Virology Unit at Institute for Medical Research, discussed the reasons for epidemic outbreaks in Malaysia, and the challenges associated with dengue surveillance and dengue serotypes in Malaysia.
Dry eye disease (DED) is a multifactorial condition characterized by tear film instability, and results in ocular discomfort and visual disturbance, and may impact patient’s quality of life such as reading and driving at night. The outer most lipid layer of the tear film, formed by the meibum, helps to maintain tear film stability by reducing the rate of tear evaporation. Alteration in the tear lipid layer, because of impaired quality or quantity of the meibum, is one of the most common causes of evaporative DED.
The recent Myeloproliferative Neoplasms Expert Forum: Deep Dive into ERNEST saw Professor Alessandro M. Vannucchi, professor of hematology at the University of Florence, Italy, present an analysis on the ERNEST registry and study, and the subsequent updated ERNEST study. He delved into the patient cohort, benefits in overall survival and symptoms, and answered the perennial question of whether Jakavi® (ruxolitinib) provides absolute improvements in myelofibrosis (MF) survival.
The prevalence of OA, which is the most common cause of disability in the aged population, is increasing in Malaysia owing to a combination of risk factors such as older age and obesity. A COPCORD study conducted in Malaysia found that 64.8% of all joint-related complaints were knee related; among patients assessed for knee pain, over half showed clinical evidence of OA. While the 2013 Malaysian CPG on the Management of Osteoarthritis recommends a linear step-up approach in managing knee OA, monotherapy is often inadequate in relieving pain symptoms and functional limitations experienced by patients with arthritis.
In a virtual lecture series sponsored by Viatris, Dr Dolores Bonzon spoke about the importance of blood pressure (BP) control and recommendations for pharmacologic treatment in the management of paediatric hypertension (HTN). She also discussed the diagnosis and treatment of a paediatric patient with HTN from her practice.
At the recent regional Myeloproliferative Neoplasm (MPN): New Horizons, A Cross-Country Webinar supported by Novartis, Dr Francesco Passamonti, professor of haematology, University Hospital Ospedale di Circolo, Fondazione Macchi, Varese, Italy, addressed the current landscape of treatment surrounding Myelofibrosis (MF) and improving survival outcomes.
3.9 million Malaysians have diabetes, representing a staggering 1in 5 adults. We also have the highest rate of diabetes in Asia and to compound matters, more than half of them will develop chronic kidney disease (CKD) during their lifetime. The incidence of CKD is also rising relentlessly year after year, evolving rapidly into not only a Malaysian, but a global non-communicable disease pandemic. Progressive CKD may not only lead to end-stage renal disease but markedly increases mortality risks, where this grows more than ten times fold if one happens to have CKD.
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Psoriasis (PsO) is a chronic, systemic immune-mediated inflammatory disease that is associated with significant cardiovascular (CV)comorbidities.1,2 Recently, MIMS Doctor spoke to Dr Norazirah Md Nor, a Consultant Dermatologist at KPJ Ampang Puteri Specialist Hospital to gather her thoughts on the impact of early treatment on disease prognosis, and to understand the link between the severity of PsO and the risk of CV diseases (CVDs). Here are the highlights from the interview.